利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

43 条记录 (耗时 0.035 秒)

    Xanthine derivatives
    2.
    发明授权
    Xanthine derivatives 失效
    黄嘌呤衍生物

    公开(公告)号：US5290782A

    公开(公告)日：1994-03-01

    申请号：US839690

    申请日：1992-02-24

    申请人： Fumio Suzuki ,  Junichi Shimada ,  Akio Ishii ,  Tetsuji Ohno ,  Akira Karasawa ,  Kazuhiro Kubo ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Junichi Shimada ,  Akio Ishii ,  Tetsuji Ohno ,  Akira Karasawa ,  Kazuhiro Kubo ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/20 ,  C07D473/22 ,  C07D473/02 ,  A61K31/52

    CPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/20 ,  C07D473/22

    摘要： Novel xanthine compounds represented by the following formula: ##STR1## wherein each of X.sup.1 and X.sup.2 independently represents oxygen or sulfur; and Q represents; ##STR2## where ----- represents a single bond or a double bond; Y represents a single bond or alkylene, n represents 0 or 1, each of W.sup.1 and W.sup.2 independently represents hydrogen, lower alkyl or amino, Z represents --CH.sub.2 -, --O--, --S-- or --NH--; represents ##STR3## each of R.sup.1 and R.sup.2 independently represents hydrogen, lower alkyl, allyl or propargyl; and R.sup.3 represents hydrogen or lower alkyl, and when Q represents the groups other than ##STR4## each of R.sup.1, R.sup.2 and R.sup.3 independently represents hydrogen or lower alkyl;provided that when Q is ##STR5## then R.sup.1 R.sup.2 and R.sup.3 are notsimultaneously methyl; and pharmaceutically acceptable salts thereof have a diuretic effect, a renal-protecting effect and a bronchodilatory effect.

    摘要翻译： 由下式表示的新型黄嘌呤化合物：其中X1和X2各自独立地表示氧或硫; 和Q表示; 其中-----表示单键或双键; Y表示单键或亚烷基，n表示0或1，W1和W2各自独立地表示氢，低级烷基或氨基，Z表示-CH2 - ， - O - ， - S-或-NH-。 R1和R2各自表示氢，低级烷基，烯丙基或炔丙基; 且R 3表示氢或低级烷基，并且当Q表示除R1之外的基团时，R 1，R 2和R 3各自独立地表示氢或低级烷基; 条件是当Q为时，则R1 + L，R2和R3不同时为甲基; 及其药学上可接受的盐具有利尿作用，肾脏保护作用和支气管扩张作用。

    Xanthine derivatives
    5.
    发明授权
    Xanthine derivatives 失效
    黄嘌呤衍生物

    公开(公告)号：US5756735A

    公开(公告)日：1998-05-26

    申请号：US483159

    申请日：1995-06-07

    申请人： Fumio Suzuki ,  Akio Ishii ,  Hiromi Nonaka ,  Nobuo Kosaka ,  Shunji Ichikawa ,  Junichi Shimada

    发明人： Fumio Suzuki ,  Akio Ishii ,  Hiromi Nonaka ,  Nobuo Kosaka ,  Shunji Ichikawa ,  Junichi Shimada

    IPC分类号： C07D473/06

    CPC分类号： C07D473/06

    摘要： The present invention relates to novel xanthine derivatives of the formula (I) which are selectively antagonistic to an adenosine A.sub.2 receptor, and pharmaceutically acceptable salts thereof. Formula (I): ##STR1## In the formula, R.sup.1 and R.sup.2 are the same or different and each represents a hydrogen atom, a propyl group, a butyl group or an allyl group; R.sup.3 represents a hydrogen atom or a lower alkyl group; Y.sup.1 and Y.sup.2 are the same or different and each represents a hydrogen atom or a methyl group; and Z represents a substituted or unsubstituted phenyl group, a pyridyl group, an imidazolyl group, a furyl group or a thienyl group.

    摘要翻译： 本发明涉及对腺苷A2受体选择性拮抗的式（I）的新颖黄嘌呤衍生物及其药学上可接受的盐。 式（I）：（I）式中，R 1和R 2相同或不同，表示氢原子，丙基，丁基或烯丙基; R3表示氢原子或低级烷基; Y1和Y2相同或不同，各自表示氢原子或甲基; Z表示取代或未取代的苯基，吡啶基，咪唑基，呋喃基或噻吩基。

    Therapeutic agent for Parkinson's disease
    6.
    发明授权
    Therapeutic agent for Parkinson's disease 失效
    帕金森病治疗剂

    公开(公告)号：US5484920A

    公开(公告)日：1996-01-16

    申请号：US133510

    申请日：1993-10-07

    申请人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shioazaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shioazaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/12 ,  A61K31/52

    CPC分类号： C07D473/08 ,  C07D473/06 ,  C07D473/12

    摘要： Agents for the treatment of Parkinson's disease contain, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## in which R.sup.1, R.sup.2 are R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 represents cycloalkyl, --(CH.sub.2).sub.n --R.sup.5 (in which R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or ##STR2## in which Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z represents substituted or unsubstituted aryl, ##STR3## in which R.sup.6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m represents an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 represent independently O or S.

    摘要翻译： 用于治疗帕金森病的药物含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐。 黄嘌呤衍生物由下式表示：其中R 1，R 2为R 3独立地为氢，低级烷基，低级烯基或低级炔基; 并且R 4表示环烷基， - （CH 2）n -R 5（其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0至4的整数）或其中Y 1和Y 2表示 独立地是氢，卤素或低级烷基; Z表示取代或未取代的芳基，其中R 6表示氢，羟基，低级烷基，低级烷氧基，卤素，硝基或氨基; m表示1〜4的整数，或取代或未取代的杂环基; X1和X2独立地表示O或S.

    Therapeutic agent for Parkinson's disease
    7.
    发明授权
    Therapeutic agent for Parkinson's disease 失效
    帕金森病治疗剂

    公开(公告)号：US5587378A

    公开(公告)日：1996-12-24

    申请号：US447885

    申请日：1995-05-23

    申请人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shiozaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    发明人： Fumio Suzuki ,  Junichi Shimada ,  Nobuaki Koike ,  Joji Nakamura ,  Shizuo Shiozaki ,  Shunji Ichikawa ,  Akio Ishii ,  Hiromi Nonaka

    IPC分类号： C07D473/06 ,  C07D473/08 ,  C07D473/12 ,  A61K31/52

    CPC分类号： C07D473/08 ,  C07D473/06 ,  C07D473/12

    摘要： Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the formula: ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are independently hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; and R.sup.4 is cycloalkyl, --(CH.sub.2).sub.n --R.sup.5, wherein R.sup.5 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4, or ##STR2## wherein Y.sup.1 and Y.sup.2 represent independently hydrogen, halogen, or lower alkyl; and Z is substituted or unsubstituted aryl, ##STR3## wherein R.sup.6 is hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro, or amino; and m is an integer of 1 to 4, or a substituted or unsubstituted heterocyclic group; and X.sup.1 and X.sup.2 are independently O or S.

    摘要翻译： 用于治疗帕金森病的方法包括向患者施用含有作为活性成分的黄嘌呤衍生物或其药学上可接受的盐的试剂。 黄嘌呤衍生物由下式表示：其中R 1，R 2和R 3独立地是氢，低级烷基，低级链烯基或低级炔基; 并且R 4是环烷基， - （CH 2）n -R 5，其中R 5表示取代或未取代的芳基或取代或未取代的杂环基; n为0〜4的整数，或者，其中Y1和Y2独立地表示氢，卤素或低级烷基; Z是取代或未取代的芳基，其中R6是氢，羟基，低级烷基，低级烷氧基，卤素，硝基或氨基; m为1〜4的整数，或取代或未取代的杂环基; X1和X2独立地为O或S.